ArticleAmerican journal of physiology. Heart and circulatory physiology2011
Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.
Article in American journal of physiology. Heart and circulatory physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Evaluation of Potential Molecular Targets of the Alkaloid Epiisopiloturine, Involved in Cardioprotective Effects, Using Computational Molecular Docking in an Animal Model of Cardiac Ischemia and Reperfusion.International journal of molecular sciences · 2025Article
- Network pharmacology integrated with experimental validation to elucidate the mechanisms of action of the Guizhi-Gancao Decoction in the treatment of phenylephrine-induced cardiac hypertrophy.Pharmaceutical biology · 2024Article
- Pharmacological Modulation of the CaPharmaceuticals (Basel, Switzerland) · 2023Article
- Adenosine and Adenosine Receptors: Advances in Atrial Fibrillation.Biomedicines · 2022Review
- Remote Conditioning by Rhythmic Compression of Limbs Ameliorated Myocardial Infarction by Downregulation of InflammationFrontiers in cardiovascular medicine · 2021Article
- Electroacupuncture improves myocardial ischemia injury via activation of adenosine receptors.Purinergic signalling · 2020Article
- Review
- Role of Cardiac AFrontiers in pharmacology · 2020Review
- Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection.International journal of molecular sciences · 2019Review
- Cardioprotection of PLGA/gelatine cardiac patches functionalised with adenosine in a large animal model of ischaemia and reperfusion injury: A feasibility study.Journal of tissue engineering and regenerative medicine · 2019Article
- Adenosine Receptor-Mediated Cardioprotection-Current Limitations and Future Directions.Frontiers in pharmacology · 2018Article
- Phenotyping of Mice with Heart Specific Overexpression of AFrontiers in pharmacology · 2018Article
- Adenosine receptors: regulatory players in the preservation of mitochondrial function induced by ischemic preconditioning of rat liver.Purinergic signalling · 2017Article
- Article
- Adenosine A2A and A2B Receptor Substantially Attenuate Ischemia/Reperfusion Injury in Septic rat Hearts.Cardiovascular drugs and therapy · 2016Article
- Cardiac purinergic signalling in health and disease.Purinergic signalling · 2015Review
- Adenosine inhibits renin release from juxtaglomerular cells via an A1 receptor-TRPC-mediated pathway.American journal of physiology. Renal physiology · 2013Article
- Structure-function studies with G protein-coupled receptors as a paradigm for improving drug discovery and development of therapeutics.Biotechnology journal · 2012Review
- On-pump inhibition of es-ENT1 nucleoside transporter and adenosine deaminase during aortic crossclamping entraps intracellular adenosine and protects against reperfusion injury: role of adenosine A1 receptor.The Journal of thoracic and cardiovascular surgery · 2012Article
- A2 adenosine receptors and vascular pathologies.Arteriosclerosis, thrombosis, and vascular biology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
All four adenosine receptor subtypes have been shown to play a role in cardioprotection, and there is evidence that all four subtypes may be expressed in cardiomyocytes. There is also increasing evidence that optimal adenosine cardioprotection requires the activation of more than one receptor subtype. The purpose of this study was to determine whether adenosine A(2A) and/or A(2B) receptors modulate adenosine A(1) receptor-mediated cardioprotection. Isolated perfused hearts of wild-type (WT), A(2A) knockout (KO), and A(2B)KO mice, perfused at constant pressure and constant heart rate, underwent 30 min of global ischemia and 60 min of reperfusion. The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA; 200 nM) was administrated 10 min before ischemia and for the first 10 min of reperfusion. Treatment with CHA significantly improved postischemic left ventricular developed pressure (74 ± 4% vs. 44 ± 4% of preischemic left ventricular developed pressure at 60 min of reperfusion) and reduced infarct size (30 ± 2% with CHA vs. 52 ± 5% in control) in WT hearts, effects that were blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (100 nM). Treatments with the A(2A) receptor agonist CGS-21680 (200 nM) and the A(2B) agonist BAY 60-6583 (200 nM) did not exert any beneficial effects. Deletion of adenosine A(2A) or A(2B) receptor subtypes did not alter ischemia-reperfusion injury, but CHA failed to exert a cardioprotective effect in hearts of mice from either KO group. These findings indicate that both adenosine A(2A) and A(2B) receptors are required for adenosine A(1) receptor-mediated cardioprotection, implicating a role for interactions among receptor subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.